|
| Analysis of medication strategies and outcome indicators in randomized controlled trials of traditional Chinese medicine for treating Helicobacter pylori infection |
| Hits 2 Download times 0 Received:May 12, 2026 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2026.09.08 |
| Key Words
Helicobacter pylori;traditional Chinese medicine;randomized controlled trial;quality evaluation;outcome indicator |
| Author Name | Affiliation | E-mail | | LIU Yang | Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China | | | JIANG Feng | Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China | jiangfengtcm@163.com | | PANG Chenxu | Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China | | | YU Yanhui | Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China | | | HUANG Yafang | Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China | |
|
| Abstract
|
| [Objective] To systematically retrieve and sort out the current status of randomized controlled trials（RCTs）on the treatment of Helicobacter pylori（Hp）infection with traditional Chinese medicine（TCM），present the results in the form of evidence mapping， and summarize the current evidence，progress，and existing issues in this field. [Methods] RCTs on the treatment of Hp infection with TCM published from January 2017 to June 2025 were retrieved from eight databases：CNKI，Wanfang Database，VIP，SinoMed， EMbase，Pubmed，Web of Science，and Cochrane Library. The quality of the literature was evaluated，and the medication strategies for both Western and Chinese medicines，as well as the setting of outcome measures，were analyzed. [Results] A total of 280 RCTs were included，with generally low quality of evidence，with issues such as non-standard antibiotic dosages and treatment durations，unclear primary and secondary outcome measures，confusion in the evaluation of composite outcome measures. [Conclusion] TCM has advantages in the treatment of Hp infection. Replacing one antibiotic with Chinese medicine and staged treatment expand the advantages of TCM，and provide a solution to the challenges in treating Hp infection. In the future，clinical design should be further standardized to enhance the quality of clinical research. Large-sample，multicenter RCTs should be conducted to provide high-quality evidence for the treatment of Hp infection with TCM. |
|
|
|
|
|
|
|
